[{"orgOrder":0,"company":"Edith Wolfson Medical Center","sponsor":"Orgenesis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Tumor infiltrating lymphocytes","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Edith Wolfson Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Edith Wolfson Medical Center \/ Orgenesis","highestDevelopmentStatusID":"1","companyTruncated":"Edith Wolfson Medical Center \/ Orgenesis"}]

Find Clinical Drug Pipeline Developments & Deals by Edith Wolfson Medical Center

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Clinical study will be undertaken with goal of utilizing and validating a number of Orgenesis’ proprietary POCare Technologies, including an automated cell culturing system for the generation and expansion tumor infiltrating lymphocytes for use in adop...

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          June 01, 2020

                          Lead Product(s) : Tumor infiltrating lymphocytes

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Orgenesis

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank